SCM
SPRY icon

Sterling Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Sterling Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73K Sell
216
-167
-44% -$1.44K ﹤0.01% 3029
2026
Q1 		$3.08K Sell
383
-19
-5% -$182 ﹤0.01% 2886
2025
Q4 		$4.68K Buy
402
+259
+181% +$2.52K ﹤0.01% 2911
2025
Q3 		$1.44K Buy
143
+10
+8% +$144 ﹤0.01% 3025
2025
Q2 		$2.32K Buy
133
+82
+161% +$1.18K ﹤0.01% 2882
2025
Q1 		$642 Hold
51
– – ﹤0.01% 2923
2024
Q4 		$538 Hold
51
– – ﹤0.01% 3022
2024
Q3 		$740 Buy
+51
New +$607 ﹤0.01% 2689

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Sterling Capital Management's SPRY Position: Q2 2026 in Review

Sterling Capital Management reduced its ARS Pharmaceuticals (SPRY) stake by 44% in Q2 2026, selling an estimated $1.44K and leaving 216 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #3029.

Sterling Capital Management first reported a position in SPRY in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.68K in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Sterling Capital Management held 216 shares of ARS Pharmaceuticals worth $1.73K as of Q2 2026.
  • Sterling Capital Management sold 167 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.44K.
  • ARS Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3029 holding.
  • Sterling Capital Management first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's ARS Pharmaceuticals position peaked at $4.68K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.